Sign in Subscribe

Michelle Whirl-Carrillo, Director and Co-PI

CPIC Guideline Update for Allopurinol and HLA-B*58:01 Published

The 2015 update of CPIC guideline for allopurinol and HLA-B*58:01 has been published in Clinical Pharmacology and Therapeutics. CPIC extensively reviewed the recent literature and concluded that the dosing recommendations provided in the 2013 CPIC guideline have not changed. The 2015 update includes the following additions: * Updated evidence

March/April SNPits Summary

In the March/April issue of UF Health Personalized Medicine Program's e-newsletter, SNPits, a recent study in the Lancet supports the benefit of pharmacogenomic testing for warfarin dosing is reviewed. The authors found that those patients with warfarin-sensitive genotypes were more likely to be over-anticoagulated in the first

NIGMS announces funding changes for PGRN

NIGMS announces the transition of pharmacogenomics research from set-aside funding to regular competition. The FOA for Research Centers for Pharmacogenomics in Precision Medicine (P50) is discontinued for 2015 and 2016. Starting in mid-July, any investigator interested in PGx can join the Pharmacogenomics Research Network through the PGRN website.

PharmGKB and Stanford Law School student collaboration

The Stanford Law School blog recently highlighted the collaboration between Stanford law students and PharmGKB to write a response to the FDA proposed regulation of laboratory developed tests. Read more about the Juelsgaard Intellectual Property and Innovation Clinic students and their work.

FDA Proposed Regulation of Laboratory Developed Tests (LDTs)

Dear Colleagues, As you may know, the FDA is considering regulating laboratory developed tests (LDTs) and had an open comment period that ended February 2, 2015. We would like to share with you a response that we wrote from our perspective at PharmGKB, working with the Stanford Law School “IP

Genomic CDS Sandbox

<!-- /* Font Definitions */ @font-face {font-family:"ＭＳ明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"ＭＳ明朝"; mso-font-charset:78; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2

CPIC Term Standardization Survey Has Been Released

In December 2014, we wrote a blog entry about the CPIC term standardization project. CPIC (Clinical Pharmacogenetics Implementation Consortium) is leading an effort to standardize terms for clinical pharmacogenetic tests, and the terms will be used in future CPIC guidelines. The hope is for the terminology to be adopted by

PharmGKB: an example of Precision Medicine

"21st century businesses will rely on American science, technology, research and development. I want the country that eliminated polio and mapped the human genome to lead a new era of medicine — one that delivers the right treatment at the right time. In some patients with cystic fibrosis, this approach

December SNPits Summary

In the December issue of UF Health Personalized Medicine Program's e-newsletter, SNPits, a recent study by Lee, et al. entitled "DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment" is reviewed. The authors find a statistically significant association between DPYD*2A and rs67376798

CPIC Term Standardization

CPIC (Clinical Pharmacogenetics Implementation Consortium) is leading an effort to standardize terms for clinical pharmacogenetic tests. The goal of the project is to create standardized terms to be used in CPIC guidelines (specifically Tables 1 and 2) and in the larger pharmacogenetics community. A list of phenotype term options based